BRAF and melanoma: Early 2014, FDA approved a combination of BRAF inhibitor (dabrafenib) and MEK1/2 inhibitor (trametinib) for the treatment of late stage malignant melanoma, due to ineffectiveness of vemurafenib monotherapy.